Rontalizumab

Rontalizumab is a humanized monoclonal antibody[1] being developed by Genentech.[2] As of November 2009, it is being investigated in a clinical trial for the treatment of systemic lupus erythematosus.[3][4]

Rontalizumab
Monoclonal antibody
TypeWhole antibody
SourceHumanized
TargetIFN-α
Clinical data
ATC code
  • none
Identifiers
CAS Number
ChemSpider
  • none
UNII
KEGG
Chemical and physical data
FormulaC6486H9990N1722O2026S44
Molar mass145917.93 g·mol−1
 NY (what is this?)  (verify)

References

  1. WHO Drug Information
  2. Genentech: Rontalizumab (rhuMAb IFN alpha)
  3. Clinical trial number NCT00962832 for "A Study to Evaluate the Efficacy and Safety of Rontalizumab in Patients With Moderately to Severely Active Systemic Lupus Erythematosus (ROSE)" at ClinicalTrials.gov
  4. Misra DP, Negi VS (March 2017). "Interferon targeted therapies in systemic lupus erythematosus". Mediterranean Journal of Rheumatology. 28 (1): 13–19. doi:10.31138/mjr.28.1.13. PMC 7045923. PMID 32185249.


This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.